Background: To find the maximum tolerated dose for ifosfamide in combination with paclitaxel and carboplatin in small-cell lung cancer patients (SCLC), who are resistant to cyclophosphamide, doxorubicin and etoposide (CDE).
Introduction
Small-cell lung cancer (SCLC) is characterised by its sensitivity to chemotherapy, which will initially induce a major response in more than 80% of patients [1] . Patients relapsing within three months after induction chemotherapy are considered resistant to the drugs used in the previous regimen [2] [3] [4] [5] . Second-line treatment should preferably consist of chemotherapy with so called noncross-resistant drugs. In a previous study from our institutions we found that paclitaxel showed significant activity in patients with an early relapse of SCLC [6] . Recently, we combined paclitaxel with carboplatin in resistant SCLC patients inducing a response rate of 73% (95% confidence interval (CI): 53%-85%) and one-year survival rate of 20% (95% CI: 11%-41%), which compares favourably to other second-line treatments [7] . Still, more active chemotherapy regimens are needed to improve results of SCLC treatment. In SCLC combination chemotherapy has shown superior activity and increased survival compared to single-agents.
The addition of ifosfamide to cisplatin and etoposide obtained superior response rates and survival in patients with extensive disease SCLC [8] . Ifosfamide has also shown anti-tumour activity in resistant SCLC after vincristine, doxorubicin and etoposide, and after cyclofosfamide, doxorubicin and etoposide (CDE) [4, 9] . Therefore, we were interested to add ifosfamide to the active combination of paclitaxel and carboplatin in patients with resistant SCLC. This combination has been used in chemotherapy-naive patients with advanced non-small-cell lung cancer and in metastatic head and neck cancer, with comparable dose levels as in our schedule. Toxicity of this regimen consisted mainly of neutropenia, arthralgia, myalgias, and sensory neuropathy [10, 11] .
We performed a dose-finding study of ifosfamide added to paclitaxel and carboplatin in patients with SCLC resistant to CDE, which is the current standard first-line regimen for SCLC patients within the EORTC-LCSG. Toxicity of the combination paclitaxel and carboplatin in this group of patients was known from our previous study [7] . To enable combination with ifosfamide we lowered carboplatin from AUC 7 to 6 mg/ml • min. To achieve prolonged cytotoxic levels of active ifosfamide metabolites we started with a schedule of infusing ifosfamide for two consecutive days. To investigate whether the pharmacokinetic parameters of ifosfamide were relevant for haematological toxicity we performed pharmacokinetic analysis of ifosfamide.
Patients and methods
The local Medical Ethical Committees approved the study. All patients gave written informed consent before they were enrolled into the study.
Eligibility criteria
Patients were considered eligible when they met all of the following criteria age between 18 and 75 years, histological or cytological proof of SCLC, progression within 3 months after previous CDE. Eastern Cooperative Oncology Group performance status 0-3. white blood cell count >3.0 x |0 9 /l. platelet count > 100 x 1O 9 /1 (unless lower values were due to bone marrow involvement), creatinine clearance > 60 ml/min. bilirubin level < 25 umol/1, and measurable or evaluable disease. Uncontrolled infection was an exclusion criterion Prior and concurrent radiotherapy was allowed, provided that not all measurable lesions were included in the irradiated field.
Evaluation before and during treatment
Before each chemotherapy cycle patients were evaluated by medical history, physical examination with assessment of performance status, complete blood cell count, liver function tests and serum creatinine, chest radiograph and/or computed tomography of the chest and if indicated other staging procedures, such as ultrasound of the liver or bone scan. During the first cycle a complete blood cell count and assessment of non-haematological toxicity was obtained on days 8. 10. 12, 15 and 22 and during subsequent cycles at least on days 8. 15 and 22. Toxicity was scored using Common Toxicity Criteria of the National Cancer Institute (CTC)
Treatment
Ifosfamide (Holoxan, ASTA Medica, Diemen, The Netherlands) was delivered in vials with dry powder and the calculated dose was dissolved in distilled water and administered as an intravenous infusion in glucose 5%. Ifosfamide was administered on days 1 and 2 as a onehour i.v. infusion. To prevent bladder toxicity, mesna (ASTA Medica, Diemen, The Netherlands) was administered in a total dose equivalent to the ifosfamide dose Twenty percent of the total dose of mesna was administered i.v. before and 40% simultaneously with ifosfamide infusion. Forty percent of the total dose of mesna was administered as tablets after completion of ifosfamide infusion, in order to enable outpatient treatment. Because urinary bioavailability of oral mesna is about 50%, oral mesna was administered at a double dose compared to the calculated dose, and administered in three equal portions at the end of infusion, and four and eight hours afterwards. The following dose levels of ifosfumide were planned: 1500 mg/m /day on days 1 and 2, 2000 mg/m 2 /day on days 1 and 2, 2500 mg/m 2 /day on days 1 and 2. In case DLTwas observed the dose of ifosfamide was decreased to 75% for the following cycles.
Paclitaxel (Taxol, Brisiol-Myers Squibb, Woerden, The Netherlands) was delivered as a concentrated sterile solution, 6 mg/ml in 5 ml ampoules in polyoxyethylated castor oil (Cremophor EL) 50% and dehydrated alcohol. The calculated dose of paclitaxel was diluted in a minimum volume of 250 ml and a maximum volume of 1000 ml of dextrose 5% or normal saline. Paclitaxel 175 mg/m 2 was administered as a three-hour i.v. infusion after administration of ifosfamide on day l.To avoid acute allergic reactions all patients received dexamethasone 8 mg orally 12-hour and i.v. 30 min before paclitaxel administration, clemastine 2 mg i v. and ranitidine 50 mg i.v. 30 min before administration ofpaclitaxel.
Carboplatin (Paraplatin. Bristol-Myers Squibb, Woerden, The Netherlands) was supplied as a lyophilised product that contained 150 mg carboplatin and 150 mg of mannitol as bulking agent. Immediately before use, the content of each vial was reconstituted with 15 ml water for injection, and the total dose was added to 250 ml dextrose 5% The dose of carboplatin was calculated according to the formula: dose (mg) = carboplatin clearance (ml/min) x AUC. Carboplatin clearance was calculated according to the Chatelut formula [12] . Carboplatin AUC 6 mg/ml min was administered after paclitaxel as a 30-min i.v. infusion on day 1.
Antiemetics consisted of ondansetron 8 mg twice daily for the first tree days and metoclopramide when needed. Therapy was administered every 21 days for a maximum of 4 cycles. Patients went offstudy in case of disease progression, incomplete haematological recovery two weeks after the scheduled start of the next cycle, CTC grade 3 neuropathy, or any other non-haematological toxicity CTC gTade 4.
Maximum tolerated dose (MTD)
MTD was defined as the highest dose of ifosfamide, which could be safely administered to a patient in combination with fixed doses of paclitaxel and carboplatin. MTD was assessed during the first cycle at each dose level of ifosfamide and defined as dose limiting toxicity (DLT) occurring in maximally one out of three or two out of six patients. DLTwas defined as: absolute granulocytes <0.5 x 10 9 /l for more than seven days or on day 22, febrile neutropenia, platelets < 25 x 10 9 /l or thrombocytopenia associated with bleeding, grade 3 or 4 non-haematological toxicity (excluding alopecia, nausea and vomiting) at any moment during the cycle, or persistent grade 2 toxicily at the scheduled start of the next cycle.
Tumour response assessment was performed according to WHO criteria. Time to progression and survival were measured from the date of initiation of therapy.
Pharmacokinetics of ifosfamide
During the first cycle, blood samples were collected for pharmacokinetic analysis from the contralateral arm in heparin-coated glass tubes before, at 30 min and at the end of 1 h infusion of ifosfamide. Thereafter, at 30 min, 1. 3, 7 and 24 hours. Blood samples were placed on ice-water and immediately centrifuged at 3000 rpm for 5 min at 4°C. The plasma was split in two l-ml volumes and added to 100 ul 2 uM semicarbazide solution to stabilise the 4-hydroxyifosfamide The remaining plasma was separated for ifosfamide, 2-and 3-dechloroethylifosfamide analysis. Furthermore, urine was collected for up to 24 hours after the end of the last ifosfamide infusion and analysed for ifosfamide, 2-and 3-dechloroethylifosfamide. The samples were stored at -20 °C until analysis. Gas chromatography with nitrogen phosphorous detection was used for the determination of ifosfamide, 2-and 3-dechloroethylifosfamide in urine and plasma [13] . High-performance liquid chromatography with reversed phase Cj with acetonitrile-0.025 M potassium dihydrogenphosphate (32:68 v/v) as mobile phase was used for determination of 4-hydroxyifosfamide [14] , In fact, this method measured the 4-hydroxyifosfamide-semicarbazone derivative in plasma. Detection was performed at 230 nm.
Statistical analysis
A population-based model (NONMEM) was used to calculate pharmacokinetic parameters for the formation and elimination rates for ifosfamide and each metabolite. This pharmacokinetic population model pooled all observations. The population values for the pharmacokinetic parameters of ifosfamide and its metabolites were estimated, but also the intenndividual differences between patients. By combining the population values with individual differences, the so-called Bayesian estimated individual parameters could be obtained for each patient [15] .
Toxicity is the result of each of the three drugs in this combination and their possible interaction. The most pronounced toxicity's different from those observed with paclitaxel and carboplatin in this group of patients [7] were related to the pharmacokinetic parameters of ifosfamide and its metabolites with linear regression analysis. A /'-value below 0 05 was considered to be significant. 
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Tumour response rate is presented as percentage and 95% Cl Time to progression and median survival time were calculated according to the Kaplan-Meier product-limit method.
Results

Patient characteristics
From April 1998 to February 2000 a total of 30 patients were registered in 2 Dutch hospitals. All patients were assessable for toxicity. Twenty-eight patients were evaluable for tumour response, as two patients expired during the first cycle. Table 1 lists the characteristics of all patients. The majority of patients (77%) had an ECOG performance status 0 or 1. All patients had been treated with CDE as first-line therapy and eight patients had received thoracic radiotherapy as part of their induction treatment. Prophylactic cranial irradiation had been administered to four patients. Two patients showed tumour progression during first-line chemotherapy; all others relapsed within three months after the last cycle of the previous chemotherapy. Median interval between the end of previous chemotherapy and start of this protocol treatment was 8 weeks (range 2-20), for patients progressive after first-line CDE it was 10 weeks (range 2-20), and 4 weeks (range 2-14) for patients progressive after second or third-line chemotherapy. The median number of cycles administered to these patients was 4 (range 1-4). Seventeen patients (56%) received the planned four cycles of therapy. The remaining patients were taken off therapy due to tumour progression (n = 5), toxicity (n = 4; 3 patients because of haematological toxicity and 1 patient for non-haematological toxicity), or early death (n = 4; 1 patient at day 6 during the first cycle due to tumour lysis syndrome caused by treatment, 1 patient at day 12 during the first cycle for unknown reason at home, 1 patient due to pulmonary embolism after 2 cycles and 1 patient because of disease progression after 2 cycles).
Toxicity
Haematological toxicity for the first cycle is shown in Table 2 . At the first dose level of ifosfamide (1500 mg/m 2 on days 1 and 2) DLT was reached in three out of six patients: two early death and one patient had CTC grade 4 thrombocytopenia. Therefore, for this schedule we were already beyond MTD. Thereafter, the dose of ifosfamide was decreased to 1000 mg/m 2 on days 1 and 2. At this level DLT was CTC grade 4 thrombocytopenia in two out of six patients. A delay of two weeks to administer the second cycle was necessary in five of the six patients because of persistent thrombocytopenia (n = 5) and leucocytopenia (n -1). Median duration of thrombocytopenia (< 100 x 10 9 /l) was 12 days (range 0-20). Because administration of ifosfamide divided over two days apparently increased platelet toxicity to an unexpected and unacceptable level, we decided to investigate in a subsequent study ifosfamide administration on one day with fixed dose of paclitaxel 175 mg/m 2 and carboplatin AUC 6 mg/ml • min. At the first level ifosfamide was administered at a dose of 2000 mg/m 2 on day 1, at which dose no DLT was observed. Thereafter, ifosfamide dose was increased to 3000 mg/m 2 at day 1. At this level grade 4 thrombocytopenia developed in two out of six patients and grade 3 myalgia in one patient. Delay for two weeks to administer the second cycle was necessary in three of six patients. To investigate the possible role of carboplatin to the persistent thrombocytopenia, the dose of carboplatin was decreased to AUC 5 with ifosfamide still at 3000 mg/m 2 on day 1. One out of six patients developed grade 3 thrombocytopenia for five days, and eleven out of sixteen subsequent cycles had to be delayed, mostly due to persistent thrombocytopenia. " Dose of paclitaxcl (175 mg/nr) and carboplatin (AUC 6 mg/ml min) were fixed at day I, except for the last level. Dosing (mg/m 2 ) and time of administration (at one or two days) of ifosfamide was variable. 5 10 Haematological toxicity for all cycles is listed in Table 3 . During the first cycle median time of granulocytes below 1 x 10 9 /L was 3 days (range 0-6). Granulocytopenia CTC grade 3 and 4 was observed in 49% and 19% of cycles, respectively. Febrile neutropenia did not occur. Eight patients received platelet transfusions and 18 patients received red blood cell transfusions.
Non-haematological toxicity was modest (Table 4 ). Nausea and vomiting were well controlled with antiemetics. Arthralgia and myalgia (grades 1 and 2) were observed in nine patients, which necessitated administration of non-steroid anti-inflammatory drugs in six patients. In one patient grade 3 myalgia was observed in the first cycle, which was manageable during following cycles. In 16 out of 30 patients neuropathy CTC grade 1 and 2 was encountered, usually after the second or third cycle. Neurological toxicity due to ifosfamide and hypersensitivity reactions due to paclitaxel were not observed.
Pharmacokinetic analysis of ifosfamide and its metabolites
Results of pharmacokinetic analysis are shown in Table 5 . The table shows that with different doses and schedules of ifosfamide the initial ifosfamide clearance two patients were without symptoms during protocol treatment and two patients developed progressive neurological complaints due to progressive cerebral disease.
Discussion
The goal of this study was to explore a new combination treatment for resistant SCLC patients. The principal dose-limiting toxicity appeared to be persistent thrombocytopenia. Addition of paclitaxel to single-agent carboplatin has shown a remarkably less degree of thrombocytopenia than expected with carboplatin alone. Paclitaxel seems to offer a protective effect for the carboplatininduced thrombocytopenia, which is not related to pharmacokinetic interactions, but may be explained by a direct protective effect of paclitaxel on megakaryocytes [16, 17] . We found that the addition of ifosfamide to the combination paclitaxel and carboplatin increased the level and duration of thrombocytopenia. Whether ifosfamide counteracts the protective effect of paclitaxel on megakaryocytes is not known. The described protective phenomenon of paclitaxel on thrombocytopenia might be schedule-dependant. Our scheduling (paclitaxel after ifosfamide) was based on the observation that paclitaxel preceding cyclofosfamide showed increased haematological toxicity compared to the alternate schedule [18, 19] . However, other investigators did not observe differences in toxicity due to scheduling of another taxoid (docetaxel) with ifosfamide [20] .
Ifosfamide is an inactive pro-drug. Cytochrome P450-3A4 induces the active metabolite 4-hydroxyifosfamide, which spontaneously yields the ultimate alkylating metabolite ifosforamide mustard [21] . Ifosfamide is also deactivated to the non-cytotoxic metabolites 2-and 3-dechloroethylifosfamide. Prolongation of cytotoxic concentrations of 4-hydroxyifosfamide might be possible if ifosfamide was administered over two days. However, prolonged ifosfamide administration induced myelotoxicity to such an extent that administration was limited to a single infusion. Myelotoxicity is obviously due to the combination of three cytotoxic drugs. We did not observe a relationship between the observed myelotoxicity and pharmacokinetic parameters of either ifosfamide or its metabolites. This may be due to the small sample size of patients and the small range of ifosfamide doses. It is also known that large interpatient variability in clinical toxicity exists in ifosfamide treatment, probably caused by interpatient differences in the extent of auto-induction of enzymes necessary for the metabolic breakdown of ifosfamide [22] . The other two drugs also contribute to haematological toxicity. Other investigators did not observe a relationship between haematological toxicity and pharmacokinetic parameters of paclitaxel, if combined with ifosfamide and cisplatin [23] .
Cytochrome P450 is also necessary for metabolisation of paclitaxel, especially the CYP 2C8 and 3A4 isoenzymes [24] . Interaction with activation of ifosfamide by cytochrome P450 may have occurred and may have influenced the observed increase in platelet toxicity. However, our scheduling (paclitaxel after ifosfamide) would especially increase toxicity of paclitaxel. As DLT of paclitaxel is mainly neutropenia, this explanation is not very likely [25] . Thrombocytopenia is the principal haematological toxicity of carboplatin and is related to renal function. As ifosfamide is also known to induce subclinical nephrotoxicity, especially tubular dysfunction it may be postulated that ifosfamide interacts with renal excretion of carboplatin, thereby increasing plasma carboplatin levels leading to prolonged thrombocytopenia [26, 27] . Unfortunately, carboplatin levels were not measured.
The tumour response rate in a similar group of resistant SCLC patients treated with paclitaxel and carboplatin was 73% in our previous study, with a median survival time of 31 weeks [7] . In this study addition of ifosfamide to paclitaxel and carboplatin did not increase anti-tumour activity in resistant SCLC and induced substantial toxicity. It seems questionable whether patients will benefit from the addition of this relatively low dose of ifosfamide to extend their survival. Better bone marrow reserve in previously untreated patients with SCLC may enable treatment with this threedrug combination with less haematological toxicity. Based on the results in other cancer types it should be possible to administer dosages of ifosfamide of 4000 mg/m 2 on 1 day, or 2000 mg/m 2 on two subsequent days. Moreover, based on our pharmacological results administration of ifosfamide over two days increases AUC of ifosfamide and metabolites and therefore might induce more cytotoxicity.
We conclude that in patients with resistant SCLC the maximum tolerated dose is ifosfamide 2000 mg/m 2 in combination with paclitaxel 175 mg/m 2 and carboplatin AUC 6 mg/ml • min all administered on day 1 of a 21-day cycle.
